- Home
- FMC vs TFX Comparison
FMC vs TFX Comparison
Compare FMC & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMC
- TFX
- Stock Information
- Founded
- FMC 1910
- TFX 1943
- Country
- FMC United States
- TFX United States
- Employees
- FMC N/A
- TFX N/A
- Industry
- FMC Major Chemicals
- TFX Medical/Dental Instruments
- Sector
- FMC Industrials
- TFX Health Care
- Exchange
- FMC Nasdaq
- TFX Nasdaq
- Market Cap
- FMC 4.6B
- TFX 4.8B
- IPO Year
- FMC N/A
- TFX N/A
- Fundamental
- Price
- FMC $13.90
- TFX $107.10
- Analyst Decision
- FMC Buy
- TFX Hold
- Analyst Count
- FMC 12
- TFX 10
- Target Price
- FMC $26.91
- TFX $134.88
- AVG Volume (30 Days)
- FMC 7.6M
- TFX 613.3K
- Earning Date
- FMC 10-29-2025
- TFX 11-06-2025
- Dividend Yield
- FMC 16.69%
- TFX 1.27%
- EPS Growth
- FMC N/A
- TFX N/A
- EPS
- FMC N/A
- TFX N/A
- Revenue
- FMC $3,608,400,000.00
- TFX $3,189,988,000.00
- Revenue This Year
- FMC N/A
- TFX $10.42
- Revenue Next Year
- FMC $3.27
- TFX $10.58
- P/E Ratio
- FMC N/A
- TFX N/A
- Revenue Growth
- FMC N/A
- TFX 5.42
- 52 Week Low
- FMC $12.87
- TFX $102.58
- 52 Week High
- FMC $61.26
- TFX $195.47
- Technical
- Relative Strength Index (RSI)
- FMC 17.02
- TFX 31.16
- Support Level
- FMC $12.87
- TFX $106.12
- Resistance Level
- FMC $14.31
- TFX $114.20
- Average True Range (ATR)
- FMC 1.13
- TFX 4.42
- MACD
- FMC -0.17
- TFX -1.82
- Stochastic Oscillator
- FMC 5.64
- TFX 14.82
About FMC FMC Corporation
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.